ArticleFrontiers in immunology2026
Sustained microparticle-mediated intracellular immunomodulation enhances tolerogenic dendritic cell stability and antigen-specific Treg induction.
Sihan Jia, Zachary Weiser, Meera Rajasekaran, Lia DiMitri, Peter Deak
Abstract read
In one paragraphArticle in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
5 authors.
Sihan JiaSchool of Biomedical Engineering, Drexel University, Philadelphia, PA, United States.
Zachary WeiserSchool of Biomedical Engineering, Drexel University, Philadelphia, PA, United States.
Meera RajasekaranSchool of Biomedical Engineering, Drexel University, Philadelphia, PA, United States.
Lia DiMitriDepartment of Material Science and Engineering, Drexel University, Philadelphia, PA, United States.
Peter DeakSchool of Biomedical Engineering, Drexel University, Philadelphia, PA, United States.
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6McGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MTolerogenic Dendritic Cells via Synergistic Drug Loaded Microparticles for Transplantation ToleranceR21AI185460 · NIAID · DREXEL UNIVERSITY · PI Peter Deak · 2025 to 2026
$391kNCI NIH HHS P30 CA016520NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS P30 AI045008NIAID NIH HHS R21 AI185460NIDA NIH HHS 75N95020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005
6 · The paper itselfAbstract
Tolerogenic dendritic cells (tolDCs) are a promising cell therapy platform for restoring immune tolerance, but their clinical efficacy is limited by poor phenotypic stability and short
Indexed as
Dendritic CellsImmune ToleranceImmunomodulationT-Lymphocytes, RegulatoryAnimalsFemaleHumansImidazolesMiceMice, Inbred C57BLOvalbuminToll-Like Receptor AgonistsImidazolesOvalbuminresiquimodToll-Like Receptor Agonistscell therapydendritic cellimmune tolerancemicroparticletolDC
Identifiers
PMID42807017
PMCPMC13616712
What OpenQuestion holds
Textmetadata
Read underepoch 390